Sanofi seeking partners to help introduce bacteriology products in U.S., Japan.
This article was originally published in The Gray Sheet
SANOFI DIAGNOSTICS SEEKS U.S., JAPANESE PARTNERS TO MARKET BACTERIOLOGY TESTS on fully automated systems as part of the firm's strategy to commercialize its blood culture and susceptibility testing products in the U.S. and Japan. The agreements would be similar to the R&D/marketing agreement forged in conjunction with the proposed sale of the Sanofi Access immunochemistry system to Beckman. Under the follow-up pact, Sanofi's diagnostics division, Sanofi Diagnostics Pasteur, will continue to research new reagents for Access that Beckman will commercialize ("The Gray Sheet" March 31, I&W-1).
You may also be interested in...
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.